[go: up one dir, main page]

MX2008010921A - Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados. - Google Patents

Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados.

Info

Publication number
MX2008010921A
MX2008010921A MX2008010921A MX2008010921A MX2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A
Authority
MX
Mexico
Prior art keywords
products
processes
morphinan
unsaturated ketone
beta
Prior art date
Application number
MX2008010921A
Other languages
English (en)
Inventor
Anthony Mannino
Hong Gu
Henry J Buehler
William E Dummitt
Dennis C Aubuchon
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38326629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008010921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of MX2008010921A publication Critical patent/MX2008010921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere en general a procesos para preparar productos de morfinan-6-ona altamente puros. Los procesos involucran reducir la concentración de los compuestos de cetonas alfa, beta insaturadas presentes como impurezas en los productos de morfinan-6-ona o mezclas de reacción que incluyen compuestos de morfinan-6-ona mediante tratamiento con un compuesto que contiene azufre.
MX2008010921A 2006-03-02 2007-03-02 Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados. MX2008010921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77825806P 2006-03-02 2006-03-02
PCT/US2007/005256 WO2007103105A2 (en) 2006-03-02 2007-03-02 Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds

Publications (1)

Publication Number Publication Date
MX2008010921A true MX2008010921A (es) 2008-09-03

Family

ID=38326629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010921A MX2008010921A (es) 2006-03-02 2007-03-02 Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados.

Country Status (10)

Country Link
US (8) US8871779B2 (es)
EP (1) EP1994034B1 (es)
JP (2) JP5695296B2 (es)
CN (1) CN101395159A (es)
AT (1) ATE448231T1 (es)
AU (1) AU2007224221B2 (es)
CA (1) CA2644095A1 (es)
DE (1) DE602007003197D1 (es)
MX (1) MX2008010921A (es)
WO (1) WO2007103105A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007062184A2 (en) 2005-11-22 2007-05-31 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US8871779B2 (en) * 2006-03-02 2014-10-28 Mallinckrodt Llc Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
US20080125592A1 (en) 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
AU2007313103C1 (en) * 2006-10-17 2014-01-30 Penick Corporation Process for preparing oxymorphone
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
JP2010511725A (ja) * 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド オキシコドン塩基中の不純物を減少させる方法
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
FR2923484B1 (fr) 2007-11-09 2012-11-09 Sanofi Aventis Procede de preparation de composes morphiniques
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
NZ596668A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Oxidation-stabilized tamper-resistant dosage form
AU2011274361B2 (en) * 2010-07-02 2014-09-18 Macfarlan Smith Limited Process for the synthesis and purification of oxycodone
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
PE20141650A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104507947B (zh) 2012-07-16 2017-06-27 罗德科技公司 用于改进的阿片样物质合成的方法
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) * 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3094634A1 (en) 2014-01-15 2016-11-23 Rhodes Technologies Process for improved oxycodone synthesis
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
CA2954600A1 (en) * 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2016187522A1 (en) * 2015-05-20 2016-11-24 Noramco, Inc. Process for the preparation of oxymorphone freebase
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
WO2022094470A1 (en) * 2020-11-02 2022-05-05 Rhodes Technologies Process for purifying noroxymorphone
CN114634514B (zh) * 2022-04-14 2024-04-09 甘肃农垦药物碱厂有限公司 一种去甲羟吗啡酮中杂质的去除方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009181A (en) * 1935-07-23 Process for obtaining opium alka
US1479293A (en) * 1924-01-01 Hiabtor fbettlid
FR1000543A (fr) 1946-02-26 1952-02-13 Roussel Uclaf Procédé d'extraction des alcaloïdes de l'opium
GB713689A (en) 1952-02-08 1954-08-18 T And H Smith Ltd A process for the extraction of alkaloids from poppy straw and/or capsules
US4435572A (en) * 1978-04-26 1984-03-06 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of ethyl-4(3'-methoxyphenyl)-1-methyl piperidine-3-carboxylate
NO793297L (no) 1978-10-19 1980-04-22 Mallinckrodt Inc Fremgangsmaate til fremstilling av oksymorfon
JPS55102538A (en) * 1979-01-30 1980-08-05 Kawasaki Kasei Chem Ltd Preparation of p-n-alkyl benzoate
IT1129758B (it) * 1980-01-23 1986-06-11 Montedison Spa Processo per la riduzione catalitica di chetoni insaturi
US4410700A (en) * 1980-07-03 1983-10-18 The United States Of America As Represented By The Department Of Health And Human Services Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution
US4556712A (en) * 1981-05-20 1985-12-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines
US4368326A (en) * 1980-07-03 1983-01-11 Rice Kenner C Short total synthesis of dihydrothebainone, dihydrocodeinone, and nordihydroccodeinone
US4727146A (en) * 1980-07-03 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction
US4521601A (en) * 1981-05-20 1985-06-04 The United States Of America As Represented By The Department Of Health & Human Services Practical total synthesis unnatural enantiomers of opium-derived morphinans
US4613668A (en) * 1983-12-22 1986-09-23 The United States Of America As Represented By The Department Of Health And Human Services Short total synthesis or morphinan compounds which uses cyclization of a cycloalkylcarbonyl compound selected from cyclopropylcarbonyl and cyclobutylcarbonyl
JPS60193902A (ja) 1984-03-16 1985-10-02 Mitsui Toatsu Chem Inc 害虫防除用組成物
US5459264A (en) 1992-12-21 1995-10-17 Shionogi Seiyaku Kabushiki Kaisha Method for reducing an α β-unsaturated ketone
HU223345B1 (hu) 1995-12-20 2004-08-30 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Eljárás alfa, béta-telítetlen ketonok sztereoszelektív redukciójára
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
TW201509943A (zh) * 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
WO2006084389A1 (de) * 2005-02-11 2006-08-17 Cilag Ltd. Verfahren zur reinigung von noroxymorphon-verbindungen
PL1861405T3 (pl) * 2005-03-04 2009-10-30 Euro Celtique Sa Sposób redukcji alfa, beta -nienasyconych ketonów w kompozycjach opioidowych
WO2007062184A2 (en) * 2005-11-22 2007-05-31 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US8871779B2 (en) * 2006-03-02 2014-10-28 Mallinckrodt Llc Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
AU2007313103C1 (en) * 2006-10-17 2014-01-30 Penick Corporation Process for preparing oxymorphone
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US8217175B2 (en) * 2007-03-23 2012-07-10 Mallinckrodt Llc Preparation of oxymorphone from oripavine

Also Published As

Publication number Publication date
US20190381033A1 (en) 2019-12-19
US20080312442A1 (en) 2008-12-18
JP5695296B2 (ja) 2015-04-01
US20200338068A1 (en) 2020-10-29
US20180008596A1 (en) 2018-01-11
US20160243113A1 (en) 2016-08-25
AU2007224221B2 (en) 2013-02-14
US20220079938A1 (en) 2022-03-17
WO2007103105A2 (en) 2007-09-13
US20150148365A1 (en) 2015-05-28
AU2007224221A1 (en) 2007-09-13
ATE448231T1 (de) 2009-11-15
CA2644095A1 (en) 2007-09-13
EP1994034B1 (en) 2009-11-11
CN101395159A (zh) 2009-03-25
WO2007103105A3 (en) 2007-11-22
EP1994034A2 (en) 2008-11-26
US8871779B2 (en) 2014-10-28
DE602007003197D1 (de) 2009-12-24
JP2009528366A (ja) 2009-08-06
JP2013173765A (ja) 2013-09-05
US20120059167A1 (en) 2012-03-08
US8748611B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
MX2008010921A (es) Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados.
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
MY157365A (en) Chemical compounds and uses
WO2008013840A3 (en) Erastin analogs and uses thereof
SI1881967T1 (sl) Substituirane benzo(d)izoksazol-3-il-aminske spojine kot analgetiki
MX2009013546A (es) Composicion acuosa que contiene una sal, proceso de fabricacion y su uso.
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
IL187586A0 (en) Method for producing dihydroquinazolines
PL2112153T3 (pl) Sposób zmniejszania ilości alfa, beta-nienasyconych ketonów w kompozycjach opioidowych
TW200612892A (en) Novel compounds
BRPI0507968A (pt) oxidação de compostos orgánicos a ph alto
TNSN08513A1 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
IL222787A0 (en) Process for preparing nebivolol
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
PH12012501052A1 (en) Novel spiropiperidine compounds
WO2008073332A3 (en) Creatine compositions for skin treatment
MX2009007695A (es) Compuestos complejos de carbohidrato de hierro.
MY151017A (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
MX2009005938A (es) 6-oxo-1,6-dihidro-pirimidin-2-ilos en el tratamiento de enfermedades proliferativas.
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
TW200700071A (en) Novel use
IL183104A0 (en) Method for production of candesartan
SI1831239T1 (sl) Postopek za pripravo gamma laktona hidroksi beta beta beta beta bismetilen alfa pregn en on karboksilne kisline in ključniintermediati za ta postopek
TW200738650A (en) Process for synthesis of aryloxy diaminopyrimidines
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status